← Back to patent-cliff list
ML-004
Tier C — Watch / tradeML-004
MapLight Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT
Indications (approved)：自闭症谱系障碍
Regional status
US
Phase II
2022-09-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ML-004?
Approved indications include: 自闭症谱系障碍.
When does the ML-004 patent expire?
No public expiry year is available for ML-004 yet; this page updates once verified.
How do I get a quote for ML-004 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05